Arcturus Therapeutics Holdings Inc. reported a total revenue of $152.3 million for the fiscal year ending December 31, 2024, a decrease of 9% from $166.8 million in 2023. The decline was primarily attributed to a $19.4 million drop in collaboration revenue, mainly due to reduced milestone achievements under the collaboration agreement with CSL Seqirus. However, grant revenue increased by 54% to $13.9 million, reflecting a rise in reimbursable research and development expenses from a grant agreement with the Biomedical Advanced Research and Development Authority (BARDA). The company continues to operate at a loss, with a net loss of $80.9 million for 2024, compared to a loss of $29.7 million in the previous year.
In terms of operational developments, Arcturus achieved significant milestones in 2024, including the commercial launch of its self-amplifying mRNA vaccine, KOSTAIVE, in Japan in October 2024, following its approval in November 2023. The company also received approval from the European Commission for KOSTAIVE in February 2025, further validating its mRNA technology platforms, STARR and LUNAR. The company has initiated several clinical trials, including a Phase 1 trial for a seasonal influenza vaccine and a Phase 2 trial for its candidate targeting ornithine transcarbamylase (OTC) deficiency.
As of December 31, 2024, Arcturus had approximately 176 employees, a slight increase from the previous year. The company continues to focus on expanding its pipeline of mRNA-based vaccines and therapeutics, particularly in the areas of infectious diseases and rare genetic disorders. The company’s cash and cash equivalents totaled $237.0 million, down from $292.0 million in 2023, indicating a need for ongoing capital to support its research and development activities.
Looking ahead, Arcturus anticipates continued losses as it invests in the development of its product candidates and seeks regulatory approvals. The company is dependent on its collaboration with CSL Seqirus for the commercialization of KOSTAIVE and other mRNA vaccines, and it plans to raise additional capital to fund its operations. The future success of Arcturus will hinge on its ability to execute on milestones within its collaboration agreements, secure additional funding, and successfully navigate the regulatory landscape for its product candidates.
About Arcturus Therapeutics Holdings Inc.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.